Oktay Faysal Tertemiz

Oktay Faysal Tertemiz

Auto-generated profile, based on publicly available information

Oktay Faysal Tertemiz

Izmir City Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Psychology, Health & Medicine
Verified
Journal Article
Closed access
NÇNazlı Nur ASLAN ÇİN
Nazlı Nur ASLAN ÇİN
MAMurat Açık
Murat Açık
OTOktay Faysal Tertemİz
Oktay Faysal Tertemİz
ÇAÇile Aktan
Çile Aktan
DADidem Tuba Akçali
Didem Tuba Akçali
AÖAyşe Özfer Özçelİk
Ayşe Özfer Özçelİk
It has recently been observed that microorganisms in the gut can regulate brain processes through the gut microbiota-brain axis, affecting pain, depression, and sleep quality. Consequently, prebiotics and probiotics may potentially improve physical, psychological, and cognitive states in those with fibromyalgia syndrome (FMS) who have an altered microbiota balance. In a randomised, double-blind, placebo-controlled clinical trial to determine the effects of probiotic and prebiotic treatments on pain, sleep, quality of life, and psychological distress (depression and anxiety) in FMS, 53 female participants with FMS were randomised to receive either: 1) 4 × 1010 CFUs per day for the 18 patients in the probiotics group; 2) 10 g dose inulin per day for the 17 patients in the prebiotic group; or 3) a placebo for 8 weeks for the 18 patients in this group. The mean ages of the groups were similar and there was no significant difference between the groups. The impact of FMS on pain, sleep quality, quality of life, anxiety, and depressive symptoms were measured at baseline, 4 weeks, and 8 weeks post-intervention. Probiotic supplementation significantly decreased the Beck Depression Index (BDI), Beck Anxiety Index (BAI), and Pittsburgh Sleep Quality Index (PSQI) scores compared to baseline, while prebiotic supplementation only significantly decreased PSQI scores. Moreover, participants who received probiotic treatment presented a significantly reduced Visual Analogue Scale (VAS) score compared with those who received placebo treatment, after the interventions. Probiotic supplementation significantly improved sleep quality, depression, anxiety, and pain scores compared to those at baseline in FMS patients, while prebiotic supplementation significantly improved pain scores and sleep quality. The potential benefits of using probiotics for treatment management in FMS patients is supported by the results of the current study and might provide an important strategy to combat FMS-associated diseases.

28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
NTNermin Tepe
Nermin Tepe
OTOktay Faysal Tertemi̇z
Oktay Faysal Tertemi̇z
Background /aim: In this study we aimed to compare the efficacy of greater occipital nerve (GON) block alone and GON combined with supraorbital nerve (SON) block was evaluated in the treatment of medication overuse headache (MOH) . 82 patients were divided into two groups; 41 patients were administered bilateral GON block and the other 41 patients GON + SON block. Nerve blocks were administered every 10 day for total 5 sessions. After each administration and 20 days after the last injection, pre and post treatment numerical rating scale (NRS) score, number of painful days, analgesic intake, duration of pain were collected. The decrease in headache evaluation parameters was similar in both groups after the block. The NRS scores in the GON and GON + SON groups before the treatment was 8.2 ± 0.7, 8.5 ± 0.7, the number of painful days in a month was 21.4 ± 6.9, 21.2 ± 4.6 days, the number of analgesics taken monthly was 45 ± 25.6, 47.5 ± 29.9, the duration of pain was 44.9 ± 24.6, 41.7 ± 22.8 hours respectively. On the 60th day of treatment, the NRS scores in the GON and GON + SON groups was found to be 6.8 ± 2.5, 4.8 ± 2.3, the number of painful days in a month was 4.2 ± 3.3, 2.2 ± 1.5, respectively. The number of monthly analgesic consumption was 4.4 ± 3.8, 0.9 ± 1.2, the duration of pain was 28.4 ± 19.3, 19.4 ± 16.1 hours, respectively. This study showed significant reductions in headache parameters in both groups. However NRS score, analgesic intake, number of painful days and in pain duration significantly better improved in the GON block added to SON block group.

31 December 2022 in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
OTOktay Faysal Tertemi̇z
Oktay Faysal Tertemi̇z
NTNermin Tepe
Nermin Tepe
Amaç: Botulinum toksini tip A, kronik migrenin önleyici tedavisi için iyi tolere edilen bir seçenek olarak kabul edilmiştir. Bu çalışmanın amacı, kronik migren tedavisinde botulinum toksin uygulamasının baş ağrısı atak sıklığını, atak şiddetini ve uygulama sayısı artıkça etkinliğinin nasıl olacağını değerlendirmektir. Gereç ve Yöntemler: Medikal tedaviye dirençli kronik migren hastalarından üç ay arayla botulinum toksin A yapılmış hastalardan toplam 29 hastanın verisi toplandı. Demografik verileri, tedavi öncesi aylık atak sıklığı, atak şiddeti, ilacın etkinlik süresini karşılaştırıldı. Bulgular: Botulinum toksini tip A uygulama öncesi ile üçüncü uygulama sonrası karşılaştırıldığında, migren ataklarının aylık sıklığında (21.7 'e karşı 11.4 gün) ve Nümerik derecelendirme skorunda (9.2 'e karşı 5.6) önemli ölçüde iyileşme bulundu (p<0.001). Botulinum toksin etkinliğinin süresi ilk uygulama sonrasında ortalama 3 ay 18 gün, ikinci uygulama sonrasında 3 ay 7 gün, üçüncü uygulama sonrasında 4 ay olarak bulundu. Sonuç: Bu çalışma, Botulinum toksini tip A uygulanan kronik migrenli hastalarda baş ağrısı atak sıklığında ve şiddetinde azalma gösterdi. Uygulama sayısı artıkça hastaların ağrısız gecen sürelerinde de artış bulundu.

31 December 2025 in Batı Karadeniz Tıp Dergisi
Verified
Journal Article
Closed access
EOErkan Ozduran
Erkan Ozduran
LILeyla İyIlikçi
Leyla İyIlikçi
VÖVesile Öztürk
Vesile Öztürk
MKMüge Mercan Kara
Müge Mercan Kara
YEYüksel Erkin
Yüksel Erkin
VHVolkan Hanci
Volkan Hanci
Aim: Herbal products, which are among the complementary medicine methods today, maintain their popularity alongside conventional treatment. The use of herbal products by individuals undergoing medical intervention may have important clinical consequences in terms of drug interactions and undesirable side effects. The frequency of use and potential risks, especially in chronic health problems such as cerebrovascular disease, are aimed to be examined in this study. Material and Methods: In this cross-sectional study, the attitudes and sociodemographic characteristics of individuals towards herbal products were examined with a questionnaire applied using the face-to-face interview method to 91 participants who met the inclusion/exclusion criteria out of 108 participants who applied to the cerebrovascular diseases outpatient clinic with ethics committee approval between June 2022 and December 2023. Survey questions that participants did not want to respond due to concerns about information security, possible biases against survey participation or concerns that treatment algorithms might change were left blank.. Results: When the gender distribution of the participants was examined, it was seen that women (n: 34, 39.5%) were less than men (n:52, 60.5%). 27.5% of the participants reported that they consumed herbal products. No statistically significant relationship was found between gender and herbal product use (p=0.248). Participants stated that they mostly used herbal products to manage cerebrovascular disease and its symptoms. However, only 36.3% (n:33) of the participants stated that they were aware of the possible side effects of herbal products. Conclusion: In our study, it was determined that 27.5% (n:25) of the participants used herbal supplements and garlic was the most preferred among them. No statistically significant difference was found in the analyses conducted on the effect of gender on herbal product use (p=0.248). It is important for physicians to keep in mind that their patients may be using herbal medicine during their treatment and follow-up.

1 April 2021
Verified
Book Chapter
Open access
PDF file
OTOktay Faysal Tertemiz
Oktay Faysal Tertemiz
CBCelalattin Avni Babacan
Celalattin Avni Babacan

1 April 2021
Verified
Book Chapter
Open access
PDF file
OTOktay Faysal Tertemiz
Oktay Faysal Tertemiz
CBCelalattin Avni Babacan
Celalattin Avni Babacan